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670 The Journal of Thoracic and CardioBackground: Despite meticulous investigation of bypass techniques for deep hypo-
thermic circulatory arrest, unfavorable long-term neurologic deficits have been well
documented. Our aim was to improve brain perfusion by reducing platelet plugging
with a glycoprotein IIb/IIIa inhibitor (eptifibatide) in an experimental model of deep
hypothermic circulatory arrest–reperfusion in pigs.
Methods: Two groups of 12 piglets each (eptifibatide group [eptifibatide  unfrac-
tionated heparin] vs UFH group [only unfractionated heparin]) underwent 10
minutes of normothermic bypass, 40 minutes of cooling during cardiopulmonary
bypass (hematocrit, 30%; cardiopulmonary bypass flow, 100 mL · kg1 · min1), 60
minutes of circulatory arrest at 15°C, and a 40-minute rewarming period. Intravital
fluorescence microscopy of pial vessels at set intervals was performed.
Results: During the cooling period, there was a tendency toward reduced functional
capillary density values without statistical significance in both groups. During
reperfusion, the eptifibatide group demonstrated a significantly decreased platelet
adhesion and aggregation (at 30 minutes of reperfusion: functional capillary density,
104%  3% vs 77%  4% relative to baseline, P  .02; red blood cell velocity,
0.65 vs 0.30 mm/s, P  .004). A more rapid recovery of tissue oxygenation (P 
.001) was documented. Furthermore, a significant microvascular permeability re-
duction was achieved compared with that seen in the UFH group (P .02). The use
of eptifibatide resulted in fewer ultrastructural changes in hippocampal tissue, which
is demonstrated by histologic examination.
Conclusions: Platelet plugging reduction with the glycoprotein IIb/IIIa inhibitor
eptifibatide improves cerebral capillary blood flow and reduces cerebral ischemia in
the setting of deep hypothermic circulatory arrest. Furthermore, significant endo-
thelial cell injury and perivascular edema reduction can be achieved.
In the setting of deep hypothermic circulatory arrest (DHCA)–reperfusion hyp-oxia, various shear stress rates on cardiopulmonary bypass (CPB) during cool-ing, circulatory arrest, reperfusion, heat stress, oxidative stress, homotypic and
heterotypic blood cell interactions, and activation are just a few of the various
processes inducing cellular stress, subsequently damaging function and structures.
Brain damage is mainly caused by uneven brain reperfusion related to capillary
changes implicated in the no-reflow phenomenon.1,2 Hypoxic endothelial cell injury
leads to procoagulant response, resulting in intravascular microthrombosis, which is
enhanced by neutrophil and platelet plugging.4-8 When organ (eg, heart and brain)
ischemia caused by DHCA of 10 to 20 minutes’ duration is induced, rapid depletion
of high-energy phosphates (eg, adenosine triphosphate [ATP]) is seen, along with
mild tissue and mitochondrial swelling and loss of glycogen stores.9 Cell mem-
branes remain intact, and the cells are still viable. Reperfusion at this time allows
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Preplacement of high-energy phosphates and reversal of isch-
emic structural changes.3 Cellular injury, however, becomes
irreversible with prolonged ischemia. Anaerobic glycolysis
ceases, and sarcolemmal and mitochondrial changes occur.
Functioning mitochondria are needed for the resynthesis of
ATP during reperfusion. Reperfusion at this time can accel-
erate the destruction of irreversibly injured cells. With more
prolonged ischemia, reperfusion might not occur at all.
Possible reasons for the inability to reperfuse include cap-
illary compression caused by aggregation of blood cell
components, endothelial and parenchymal compression
from edema, and swelling of cells (glia and neurons).2
Glycoprotein IIb/IIIa receptor blockade, apart from its es-
tablished effects on maintaining large-vessel patency and
enhancing microvascular myocardial perfusion, has been
found to improve vascular nitric oxide bioavailability,
which is involved in vasomotor regulation.10 We hypothe-
sized that a significantly improved cerebral reperfusion after
DHCA could be achieved by reducing plug formation, es-
pecially at the capillary level, and by preserving endothelial
vasomotor function. This could, in turn, reduce the above-
mentioned ultrastructural brain deterioration.
Methods
Surgical Procedure
Twenty-four experiments (n  12 in each experimental group)
were performed on 3- to 4-week-old hybrid pigs (Piétrain
Halothan-Gen / and German Country Pedigree) with an aver-
age body weight of 10 to 15 kg. All animals received humane care
in compliance with the “Guide for the Care and Use of Laboratory
Animals” published by the National Institutes of Health (NIH
publication no. 85-23, revised 1985). After intramuscular premed-
ication with ketamine (20 mg/kg) and xylazine (4 mg/kg), endo-
tracheal intubation (cuffed 5-mm tube), and a bolus of fentanyl (25
g/kg administered intravenously), the piglets were artificially
ventilated with a pressure-controlled respirator by an inspiratory
oxygen fraction of 50% before CPB and 100% after CPB at a rate
of between 18 to 22 breaths/min to achieve an arterial PCO2 of
between 35 and 40 mm Hg. Anesthesia was maintained with
fentanyl (25 g · kg1 · h1), midazolam (0.2 mg · kg1 · h1),
and pancuronium (0.2 mg · kg1 · h1) by an infusion pump. A
rectal temperature probe was placed. The right femoral artery was
cannulated, and the catheter was advanced into the descending
aorta for monitoring of blood pressure and blood gases. Blood
pressure and body temperature were continuously monitored and
recorded every 10 minutes. Blood gases were checked for PO2,
PCO2, pH, potassium, and lactate every 10 minutes on CPB in
1-mL samples by a blood-gas analyzer (ABL 625, Radiometer
Medical A/S, Copenhagen, Denmark). A catheter was placed
through the right femoral vein into the inferior vena cava for
infusion of drugs and fluorescent dyes. The aorta was exposed for
arterial CPB cannulation through a right anterolateral thoracotomy
in the third intercostal space. After administration of heparin (300
IU/kg), an arterial cannula (8F; BioMedicus, Eden Prairie, Minn)
was advanced through the aorta. A 24F venous cannula (Stoeckert,
Munich, Germany) was inserted into the right atrium. The heart
The Journal of Thoraciwas not opened during the procedure. Immediately after insertion
of the catheter into the inferior vena cava, the eptifibatide group
received a bolus of eptifibatide (180 g/kg) twice at 10-minute
intervals, followed by continuous eptifibatide administration with
an infusion pump (20 g · kg1 · min1). This infusion was then
stopped at the beginning of DHCA. The animals were placed in a
prone position, and a left-sided trepanation over the left parietal
cortex was performed with an electric drill. The final size of the
hole in the skull was 15  25 mm. Bleeding from the bone and
periosteum of the fully heparinized animals was controlled with
bone wax. After incision of the dura, the pial vessels were
visualized.
Intravital Microscopy: Hardware Configuration and
Measurements
The microscopy facility used for intravital microscopy of the brain
microcirculation in anesthetized pigs is a combination of a Leica
stereo epifluorescence microscope (model MZFL III Fluo Combi;
Leica, Heerbrugg, Switzerland) with a 100-W mercury gas dis-
charge lamp equipped with a rapid filter exchanger (including 3
sets of filters) and the Leica Fluo Combi, a 3 Chip CCD camera
(Hitachi HV-C20) and a computer workstation. The microscope
was placed above the cranial window. The images from the 3 Chip
CCD camera were displayed on a high-resolution 15-inch monitor.
The microscopic images were also recorded with an S-VHS video
recorder on S-VHS tapes to back up the collected data. The final
magnification on the monitor was 400. The analysis of the
recorded images was performed offline. To visualize microvascu-
lar (diameter range, 15-180 m) perfusion, plasma was labeled
with 5% fluorescein isothiocyanate (FITC)–dextran (molecular
weight, 150,000 d; Sigma Aldrich, Munich, Germany) by intra-
vascular injection of 2 mL of FITC-dextran for baseline recordings
and 0.5 mL of FITC-dextran before each subsequent measurement
(intravenous injection before and after CPB and intra-arterial in-
jection on CPB). FITC fluorescence was excited with a 450- to
490-nm light, and the emitted light (515 nm; blue filter set,
Leica) was transferred from the microscope to a video camera.
Thus, the plasma was highlighted, and the red blood cells appeared
dark (negative contrast). The window was regularly washed with
physiologic saline solution to minimize heating of the cover slip
and the underlying tissue. For observation of leukocyte–
endothelial cell interactions, the circulating leukocytes were la-
beled by intravenous injection of 2 mL of Rhodamine 6G solution
(Sigma Aldrich) before each measurement. A green filter set
(excitation wavelength, 536-556 nm; emission wavelength, 590
nm; Leica) was used to excite Rhodamine fluorescence. Microvas-
cular perfusion and reduced nicotinamide adenine dinucleotide
(NADH) fluorescence were recorded every 10 to 15 minutes on
CPB. In addition, NADH fluorescence was recorded every 15
minutes during circulatory arrest. The duration of epi-illumination
was limited to 1 minute at set intervals to avoid thermal injury of
tissue. The epi-illumination of brain tissue was always shut off
between video recordings.
Functional Capillary Density
After focusing below the level of the pial vessels, the cortical
capillaries could be visualized because of the FITC fluorescence of
blood plasma. Functional capillary density (FCD), defined as the
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area (in centimeters), was determined as previously described by
Duebener and colleagues.11
Tissue Oxygenation
The natural intracellular fluorophore NADH, which accumu-
lates during ischemia, was used as a marker for tissue oxygen-
ation. NADH fluorescence was excited with a 340- to 380-nm
light (UV-Filter set: emission wavelength, 420 nm; Leica).
During these measurements, the remote control of the video
camera for brightness and contrast was disabled. The optical
densities (black  0, white  255) of the recorded still images
were determined by densitometry.
Red Blood Cell Velocity
Microscopic images of the moving red blood cells were collected
with the high-speed 3 Chip CCD camera. A sequence at the
median plane of each vessel was recorded for offline analysis of
red blood cell velocity (RBCV) with the Cap-Image line-shift-
diagram method (Cap-Image; Ingenieurbüro Zeintl, Heidelberg,
Germany).
Microvascular Permeability
The extravasation of FITC-dextran–labeled plasma through dis-
rupted endothelial cell lining resulted in the formation of con-
fluent dye clouds, which surround the microvessels. The
perivascular optical density changes that occurred during the
TABLE 1. Experimental conditions
Parameter Group Pre-CPB 10’ NT
Arterial pH Eptifibatide group 7.6 0.06 7.5  0.0
UFH group 7.6 0.08 7.5  0.0
Arterial PCO2 Eptifibatide group 33.4 7 45.5  10
UFH group 35.1 7.4 37.6  6.5
Arterial PO2 Eptifibatide group 426.5 97.4 207.8 17
UFH group 426.7 126.9 355.2 19
Arterial
hematocrit
Eptifibatide group 29.1 1.7 29.3  3
UFH group 26.9 2 30  3.6
Rectal
temperature
Eptifibatide group 37.8 0.8 35.1  1.8
UFH group 38 0.0 33.8 2.2
Mean arterial
pressure
Eptifibatide group 88.6 12.9 82.3 18
UFH group 72.8 16.6 87.6 23
Arterial
lactate
Eptifibatide group 2 0.6 4.1 1.9
UFH group 1.7 0.5 4.2  1.4
Platelet
count
Eptifibatide group (419 30)*103
UFH group (301 22)*103
Values for arterial pH, PCO2, and PO2 are corrected to rectal temperature. Pr
of normothermic bypass; 10’ cool, after 10 minutes of cooling; End cool, e
rewarming; Platelet count, pre-CPB compared with the end of rewarming
study group (P  .05).experiment were determined by densitometry.
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After baseline recordings of the cerebral microcirculation, CPB
was initiated. A roller pump (Stoeckert) was used to generate a
nonpulsatile pump flow of 100 mL/kg body weight in all
experiments. The gas flow was adjusted to achieve an arterial
PCO2 of 40 to 45 mm Hg. The CPB circuit in all experiments
consisted of a 1000-mL filtered hard-shell venous reservoir
(Cobe VPCML Plus; COBE Cardiovascular, Inc, Arvada,
Colo), a membrane oxygenator, a 40-m arterial filter, and
1⁄4-inch tubing. Venous drainage was by gravity. No cardiotomy
suction was used. The venous line was left open during circu-
latory arrest. A sterile circuit was used in each experiment. The
CPB circuit was primed with 800 mL of blood. The blood used
for priming of the CPB circuit to achieve a hematocrit level of
30% on CPB was drawn on the morning of the experiment from
an adult donor pig. Before the start of CPB and during reper-
fusion, methylprednisolone (25 mg/kg), cephazolin (25 mg/kg),
10 mL of sodium bicarbonate 7.4%, and furosemide (0.25
mg/kg) were added to the prime. After 10 minutes of normo-
thermic bypass, piglets underwent 40 minutes of cooling to a
rectal temperature of 15°C. After 60 minutes of DHCA, animals
were rewarmed on CPB to 37°C. After weaning from CPB, the
animals were observed for 30 minutes. The room temperature in
the animal operating room was thermostatically controlled
(range, 15°C to 30°C) to aid cooling and rewarming of animals.
No topical cooling was applied.
10’ cool End cool 10’ rewarm End rewarm
7.4  0.1 7.4 0.06 7.4 0.1 7.5  0.19
7.4  0.1 7.36 0.05 7.4  0.1 7.4  0.13
51 10.4 50.4  7 34.9 9.1 31.3  9.2
44.5  11.4 48.6 9.3 37.4 7.9 29.7  9.6
489.7 291.7 530.5 339.2 286 206.1 310.1 187.1
518.9 317.7 342.7 374.3 338.9 248.7 298.5 181.5
29.3  1.7 29 3 29.6 3.4 28.6  5
29.7  3.2 28.8  1.6 29.55 30.6  3.7
26.7  2.9 15.7  0.9 29.6 4.1 36.2  1.8
19.9  2.05 15.6 0.8 30 2.2 36.5  1.1
85.3 27.6 77.5 14 69.8 26.9 83.7 18.5
74.6 18.5 69.6 16.7 58.3 16.1 77.2 21.5
5.2  2.4 5.6 1.8 8.8 2.3 10.3 2.2
5  1.74 5.8  2.07 10.4 2 12  3.84
(279 32)*103
(104 25)*103
, Baseline values before cardiopulmonary bypass; 10’ NT, after 10 minutes
cooling; 10’ rewarm, after 10 minutes of rewarming; End rewarm, end of
ificantly higher platelet count reduction in UFH group compared with the9
9
.8
5.7
6.3
.1
.9
e-CPB
nd of
, signExperimental conditions are shown in Table 1.
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PHistopathologic Analysis
At the end of the experiment, the animals underwent bilateral
carotid perfusion with 4% paraformaldehyde in 0.1 mol/L phos-
phate buffer. The brain was then removed and dissected in smaller
tissue samples. The hippocampus was isolated, and a standard
postfixation was then performed. Ultrathin sections were cut with
an ultramicrotome (Reichert), and they were examined with a
Zeiss EM 902 electron microscope (Carl Zeiss AG, Gottingen,
Germany).
Statistical Analysis
Continuous variables are expressed as means  standard devia-
tion. Variables were tested for normality by the Kolmogorov-
Smirnov goodness-of-fit test, and no significant skewness was
detected. Repeated-measures analysis of variance was performed
to evaluate changes over time and to compare rates of change
between the groups. For time-point comparisons within an exper-
imental group, paired t tests were used. One-way factorial analysis
of variance with the post-hoc Bonferroni method was used to
evaluate group differences at fixed time points. Data analysis was
conducted with the SPSS software package (release 11.0; SPSS,
Inc, Chicago, Ill).
Results
Functional Capillary Density
There was a slight decrease of FCD relative to baseline
values during cooling in both groups. At the end of cooling,
the FCD was 98%  2% in the eptifibatide group and 84%
 3% in the unfractionated heparin (UFH) group (P .17).
During early reperfusion, there were significantly higher
FCD values in the eptifibatide group relative to the UFH
group (reperfusion start: 84% 3% [eptifibatide] vs 40%
Figure 1. FCD values were significantly lower in the UFH group
during early reperfusion (reperfusion start and 30 minutes of
reperfusion: P< .007 and>P .02, respectively). Filled columns,
UFH group; open columns, eptifibatide group. *P < .05.4% [UFH], P  .007; 30 minutes of reperfusion: 104% 
The Journal of Thoraci3% vs 77%  4%, P  .02). At the end of reperfusion and
30 minutes after weaning from CPB, the FCD was not
significantly different from baseline values in either group
(Figure 1).
Capillary Red Blood Cell Velocity
A significant cortical capillary RBCV reduction was ob-
served after 10 minutes of CPB in both groups. During
reperfusion, there was a rapid and sustained recovery of
capillary RBCV in the eptifibatide group. The UFH group
showed a delayed RBCV recovery (20 minutes of reperfu-
sion: velocity of 0.65 vs 0.30 mm/s in the eptifibatide and
UFH groups, respectively; P .004), and this did not return
to the normal value or equal value to the eptifibatide group
(Figure 2).
Tissue Oxygenation
The NADH autofluorescence of the parietal cortex slightly
decreased in the eptifibatide group at the end of cooling,
indicating better cerebral tissue oxygenation. At the same
time point, the UFH group showed no significant changes
relative to baseline. During early DHCA (at 10 minutes of
DHCA), the NADH autofluorescence reached 96%  2%
and 124%  3% in the eptifibatide and UFH groups, re-
spectively (P  .05), indicating significantly poorer tissue
oxygenation in the UFH group. This more severe deoxy-
genation in the UFH group was sustained during the entire
DHCA period and the early reperfusion period (10 minutes
Figure 2. RBCV recovery during reperfusion was more rapid in
the study group. At the end of rewarming, there was still a
significant difference between both groups. Furthermore, the
RBCV value in the UFH group at 40 minutes of reperfusion was
significantly lower than the pre-CPB value (P < .05). Filled
columns, UFH group; open columns, eptifibatide group. *P < .05.of reperfusion: 98%  2% [eptifibatide] vs 128%  3%
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baseline values was significantly shorter in the eptifibatide
group (5 vs 40 minutes, P  .001). After 10 minutes of
reperfusion, there was a complete metabolic recovery in the
eptifibatide group, whereas the metabolic recovery was in-
complete in the UFH group at the end of reperfusion.
Complete recovery was reached in this group about 30
minutes after weaning from CPB (Figure 3).
Figure 4. Microvascular permeability was increased in the UFH
group during rewarming. This increase has reached statistical
significance at 40 minutes of rewarming (P< .05). Filled columns,
UFH group; open columns, eptifibatide group. *P < .05.
674 The Journal of Thoracic and Cardiovascular Surgery ● SeptMicrovascular Permeability
During cooling and DHCA, there was a slight increase in
microvascular permeability in both groups, although this
was without statistical significance between the study and
control groups. By the end of rewarming, the microvascular
permeability had increased significantly in the UFH group
compared with that in the eptifibatide group (at 40 minutes
of rewarming and 30 minutes after weaning from CPB; P
.05, respectively), indicating a more severe endothelial lin-
ing alteration in this group (Figure 4).
Histopathologic Analysis
Morphologic investigation of hippocampal tissue that was
processed for light and electron microscopic analysis by
embedding in epoxy resin reveals marked differences in the
untreated (UFH) group versus the eptifibatide-treated group.
Ultrastructural investigation of the hippocampus confirms
and extends findings concerning the superficial cerebrocor-
tical tissue alterations in the UFH group compared with
findings in those treated with eptifibatide. Severe damage
appeared in the UFH group. Most prominent is the perivas-
cular edema formation and disintegration of the endothelial
lining from the surrounding interstitium. In the eptifibatide
group these ultrastructural tissue alterations are markedly
reduced (Figure 5).
We demonstrate in this experimental study that platelet
glycoprotein IIb/IIIa receptor blockade with eptifibatide in
the setting of DHCA-reperfusion on CPB during cardiac
surgery significantly improves cerebral capillary reperfu-
sion and significantly reduces vascular permeability. The
significantly higher FCD values during reperfusion in the
eptifibatide group compared with those in the UFH group
could likewise be shown. Damage to the endothelial cells on
Figure 3. NADH autofluorescence. Tissue oxygen-
ation was significantly lower (higher NADH
autofluorescence) in the UFH group during DHCA
and early rewarming (10 minutes of DHCA, P  .05;
10 minutes of rewarming, P < .04). Triangles, Epti-
fibatide group; squares, UFH group. *P < .05.CPB, especially during circulatory arrest, rapidly induces a
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Presponse by the attachment of platelets to the site of the
injury coupled to their activation. The initial adhesion and
activation occur in a time scale of milliseconds to seconds
and require the concerted interaction of matrix proteins with
platelet receptors. The main platelet counterparts include
collagen receptors, integrin 21, glycoprotein VI, von
Willebrand factor receptor, glycoprotein Ib, and integrin
IIb3 (glycoprotein IIb-IIIa).12 The adherent and activated
platelets become the substrate for the second phase of
platelet plug formation, which develops in a time frame of
minutes and involves the recruitment and activation of
additional circulating platelets into the growing thrombus.
This phase of homotypic aggregation depends on the for-
mation of interplatelet bonds that involve primarily glyco-
protein Ib in the glycoprotein Ib-IX-V complex and acti-
vated IIb3 as receptors on the platelet surface and plasma
von Willebrand factor and fibrinogen as the ligands that link
platelets to one another.8 Platelet inhibition by IIb3 (gly-
coprotein IIb/IIIa) blockade significantly reduces platelet
aggregation and activation. This leads to the subsequent
Figure 5. Electron microscopy: ultrastructural investig
group (a and b) and the eptifibatide group (c and d). a, E
are visible. (Original magnification 4400.) b, At a high
(Original magnification 12,000.) c, There is mild per
magnification 4400.) d, Only weak perivascular altera
Black arrow, Vacuole formation; white arrow, perivassignificantly higher FCD values in the eptifibatide group
The Journal of Thoracicompared with those in the UFH group (Figure 1). The
preservation of FCD in the eptifibatide group contributes to
the more even and homogeneous brain reperfusion (higher
RBCV). The no-reflow phenomenon becomes negligible.
Cerebral tissue oxygenation was significantly higher in the
eptifibatide group during DHCA and early reperfusion.
There are several lines of evidence that platelet-endothelium
interactions contribute to endothelial dysfunction and im-
paired nitric oxide bioactivity.13,14 Platelet glycoprotein IIb/
IIIa blockade contributes to enhanced nitric oxide bioactiv-
ity, which maintains the vasomotor activity.10,15 This,
associated with higher FCD values in the eptifibatide group,
results in enhanced capillary perfusion (higher RBCV),
which in turn explains the higher tissue oxygenation in this
group. The intravital microscopy also shows higher micro-
vascular permeability in the UFH group relative to the
eptifibatide group, which reaches statistical significance at
the end of rewarming. This is consistent with the improved
histologic findings in the eptifibatide group compared with
those in the UFH group. These results support the concept
ns of hippocampal tissue (blood vessels) in the UFH
elial degeneration (vacuoles) and perivascular edema
agnification, the perivascular edema is clearly visible.
ular edema in eptifibatide-treated animals. (Original
appear in this group. (Original magnification 12,000.)
edema formation.atio
ndoth
er m
ivasc
tions
cularthat there is improved structural preservation of the inner
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eptifibatide is used. Platelets have been shown to contain
vascular endothelial growth factor (VEGF), which is re-
leased during clotting.16 Previous studies showed that there
is concerted activation between integrins, such as integrin
v3 and VEGF2. There is a synergistic interaction be-
tween the clustered integrin receptor v3 and VEGFR2.
This is required for full phosphorylation of VEGFR2, which
increases the microvascular permeability.17 It might be such
a mechanism underlying the beneficial effect of eptifibatide
by inhibiting integrin IIb3 (glycoprotein IIb/IIIa), which
binds to multiple substrates, and consequent downregula-
tion of VEGFR2. Further investigations to clarify this
mechanism need to be carried out. One of the limitations of
this intravital microscopy study of cerebral microcirculation
is the fact that only superficial cerebrocortical vessels can be
assessed. Subcortical microvessels cannot be studied with
this direct method in a nondisruptive manner.11 However,
hypoperfusion of deeper, selectively vulnerable brain re-
gions, such as the hippocampus, caudate nucleus, and neu-
rons, is most likely important in the pathogenesis of neuro-
logic injury after DHCA. For that reason, we performed
histologic investigations (electron microscopy) of hip-
pocampal tissue. These investigations demonstrated that
there was a significant increase in histologic evidence of
brain injury in the UFH group. The markedly higher extent
of microvascular alterations after DHCA-reperfusion on
CPB in the UFH group versus the eptifibatide group high-
lights the beneficial effects of eptifibatide on homotypic and
heterotypic platelet aggregation and receptor-modulated va-
sopermeability and vasomotor activity. These data raise the
possibility that the clinical use of eptifibatide in the setting
of DHCA during cardiac surgery might have beneficial
effects on the neurologic outlook for these patients. There
was no difficulty with bleeding during the entire study.
Eptifibatide had a protective effect on platelets. A signifi-
cant preservation of the total platelet count at the end of the
experiment was documented in the study group (Table 1).
This might dissipate any reluctance for cardiovascular sur-
geons to use a platelet inhibitor of this potency. The use of
eptifibatide in a survival animal model might show the
long-term neurologic, cognitive, and behavioral benefits in
the setting of DHCA-reperfusion.
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Discussion
Dr James W. Frederiksen (Chicago, Illinois). This is nice work.
I would like to know whether you used eptifibatide in the setting
of bypass at normothermia without circulatory arrest?
Dr Ben Mime. Actually, we have a study going in which we
are using eptifibatide at normothermia without circulatory ar-
rest.
Dr Frederiksen. I think the use of eptifibatide in this setting
of bypass at normothermia could improve the microcirculation.Dr Ben Mime. It might be
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